Atracare is now Offering Treatment for Patients with COVID: Bebtelovimab

  • This is a monoclonal antibody used to treat patients with COVID.
  • It is given as a slow IV injection over 30 seconds.  Then we monitor patients for 1 hour to ensure there is no reaction.
  • This medication is for anyone ≥12 years of age and weighing at least 40 kg.
  • The dosage is bebtelovimab 175 mg administered as a single intravenous injection over at least 30 seconds.
  • Administration of bebtelovimab is recommended to occur as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset.
  • This medication is best for patients who are at high risk for progression to severe COVID-19, including hospitalization or death, and
  • for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

 

From the FDA

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant. The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms, which is about 88 pounds) with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. Treatment with bebtelovimab has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bebtelovimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

 

FDA Fact Sheet> 

To get Bebtelovimab:

Contact us via text at 302-517-1385 and we can make arrangements for you to come into to get the treatment.  You can also email us at info@aspirahealth.net to arrange an injection.

0 New comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News and Clinic Information

We are your partner in health. Stay up to date with latest news and information.

Atracare Hot Topics July 2024

Welcome to Atracare Hot Topics. In this July edition, we cover crucial health advisories, tips for surviving the severe heat wave, our stance on Governor Carney and House Bill 350, and insights from the 2024 Burden of Chronic Disease Report released by the DPH.

Read More

Atracare Hot Topic: DPH Releases 2024 Burden of Chronic Disease Report

The Delaware Division of Public Health (DPH) released the 2024 Burden of Chronic Disease in Delaware report, detailing the prevalence and impact of chronic diseases like heart disease, stroke, and diabetes. Chronic diseases account for seven of the top ten causes of death in Delaware, affecting tens of thousands and costing billions annually. Key findings highlight racial inequities and the stable or increasing prevalence and mortality rates for various conditions. DPH is committed to addressing health inequities and improving chronic disease prevention and management. Atracare supports these efforts with affordable, premium healthcare services. For more information, visit the DPH website.

Read More

Atracare: We Stand By Governor Carney and House Bill 350

Atracare supports Governor John Carney’s signing of House Bill 350, aimed at controlling healthcare costs in Delaware.  The new law establishes the Diamond State Hospital Review Board to ensure hospitals align pricing with state benchmarks, promoting transparency and reducing costs. Atracare continues to offer accessible healthcare services to Southern Delaware residents and visitors, accepting all major insurances. Visit Atracare’s clinics in Lewes or Ocean View for premium, affordable care.

Read More